Pre-existing anti-polyethylene glycol antibodies in pregnant women and newborns
Haiyang Wang,Yan Feng,Lin Zhang,Changzheng Yuan,Junyang Xue,Jicheng Li,Xiao Xu,Wenbin Zhou,Baohua Li,Yisha Wang,Gan Luo,Yue Zheng,Meihua Sui
DOI: https://doi.org/10.1101/2024.11.29.24317450
2024-12-04
Abstract:Importance: Pre-existing anti-polyethylene glycol (PEG) antibodies represent risk factors for reduced efficacy and increased adverse reactions in seropositive individuals receiving PEGylated drugs, but neither their sero-prevalence, nor levels nor potential influencing factors has been investigated in pregnant women or newborns.
Objective: To parallelly determine the sero-prevalence and levels of pre-existing anti-PEG antibodies in pregnant women and their newborns, and to reveal their independent influencing factors.
Design: Cross-sectional analysis using data of pregnant women and their newborns enrolled between May 2021 and May 2022.
Setting: Pregnant women admitted for delivery at the Women's Hospital, Zhejiang University School of Medicine in China, were approached for enrollment.
Participants: Participants included 256 pregnant women (volunteers) and corresponding 256 newborns. Major eligibility criteria for pregnant women included an age of 20 years or older, a singleton pregnancy, a full-term pregnancy, no history of unhealthy lifestyle , no previous contagious diseases and no other diseases upon enrollment.
Exposures: Maternal and cord blood samples were collected and examined for pre-existing anti-PEG antibodies, along with questionnaire interviews, demographic and clinical data collections.
Main Outcome and Measures: All blood samples underwent screening and quantification of anti-PEG antibodies. Sero-prevalence and levels of total pre-existing anti-PEG antibodies and each known isotype/subclass were determined in pregnant women and newborns. Influencing factors for sero-prevalence and/or levels of pre-existing anti-PEG antibodies in pregnant women and newborns were respectively revealed with in-depth statistical analysis.
Results: The seropositivities of total anti-PEG antibodies, anti-PEG IgG1 and IgG2, anti-PEG IgM, and co-existence of anti-PEG IgM and IgG were 19.14%, 2.34%, 7.03%, 10.94% and 1.17%, respectively in pregnant women, and 5.47%, 2.73%, 2.73%, 0% and 0%, respectively in newborns. Anti-PEG IgG3, IgG4 and IgE were detectable in neither pregnant women nor newborns. Pregnant women with anti-PEG antibodies had a median (Range; IQR) anti-PEG IgG1, IgG2 and IgM concentrations of 273.88 ng/mL (183.74-513.90; 191.70-376.08), 748.35 ng/mL (75.54-2604.89; 159.09-1200.81) and 175.07 ng/mL (55.43-23649.14; 95.95-315.19), respectively. Newborns with anti-PEG antibodies had a median (Range; IQR) anti-PEG IgG1 and IgG2 concentrations of 207.92 ng/mL (120.40-1513.98; 133.97-524.58) and 336.52 ng/mL (100.24-1069.62; 275.80-527.07), respectively. This study revealed that maternal age, take out-food consumption, cosmetic use and occupation were influencing factors of prevalence and/or levels of maternal anti-PEG antibodies, and prevalence and/or levels of newborn anti-PEG antibodies were affected by maternal age, occupation and cosmetic use.
Conclusions and Relevance: A proportion of pregnant women and newborns were found seropositive for pre-existing anti-PEG antibodies, raising efficacy and safety concerns over the use of PEGylated drugs in pregnant women and newborns. Several influencing factors on maternal and/or newborn pre-existing anti-PEG antibodies were discovered, which has provided valuable information for deeper understandings on the origins of PEG antigens and the induction of risky pre-existing anti-PEG antibodies.
Epidemiology